Advertisement
Aprea Therapeutics Inc. (APRE)
NASDAQ: APRE
· Real-Time Price · USD
1.75
0.00 (0.00%)
At close: Apr 29, 2025, 9:30 AM
0.00% (1D)
| Bid | 1.7 |
| Market Cap | 9.67M |
| Revenue (ttm) | 942.14K |
| Net Income (ttm) | -12.96M |
| EPS (ttm) | -2.35 |
| PE Ratio (ttm) | -0.74 |
| Forward PE | -2.27 |
| Analyst | Buy |
| Ask | 1.83 |
| Volume | 2,464 |
| Avg. Volume (20D) | 27,875 |
| Open | 1.79 |
| Previous Close | 1.75 |
| Day's Range | 1.75 - 1.79 |
| 52-Week Range | 1.41 - 5.90 |
| Beta | 1.62 |
About APRE
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATR...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 3, 2019
Employees 8
Stock Exchange NASDAQ
Ticker Symbol APRE
Website https://atrinpharma.com
Advertisement
Analyst Forecast
According to 2 analyst ratings, the average rating for APRE stock is "Buy." The 12-month stock price forecast is $15.5, which is an increase of 785.71% from the latest price.
Stock Forecasts1 month ago
+9.87%
Aprea Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
